Epitan raises $8 million in private placement
Wednesday, 11 August, 2004
EpiTan (ASX: EPT) has raised AUD$7.98 million via a private placement of 10.5 million fully paid ordinary with two European investors.
The shares were issued at AUD$0.76, a 6.4 per cent discount to the three-month volume weighted average price of AUD$0.91.
8.5 million shares were placed with FM Fund Management, run out of Zurich by hedge fund manager Florian Homm. Its Absolute Return Europe Fund is now a substantial shareholder in EpiTan, holding 6.8 per cent of the company’s shares.
A further 2 million shares were placed with UK biotech investment fund Mercury Investments.
Epitan also issued 6.6 million unlisted options exercisable over three years at AUD$1.03, which would provide it with a further AUD$6.87 in cash. EpiTan’s executive chairman and CEO, Dr Wayne Millen said the placement bought Epitan’s cash reserves to approximately AUD$13 million.
At time of writing shares in Epitan were trading at $0.87.
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
